Skip to content
Screener

LB Pharmaceuticals Inc LBRX Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$0.61Miss by $0.04
EPS estimate-$0.57

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$1.61

Financials

Q3 2025

Income statement

See full
Net income-$3.6M+74.9%
EPS (diluted)-$0.61+98.5%

Balance sheet

See full
Cash & equivalents$269.7M—
Total debt$3.7M—
Total equity$310.2M+439%
Total assets$320.7M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$354.37M—
Enterprise value$88.3M—

Returns & leverage

See full
Debt / equity0×—
Current ratio47.6×—

Versus estimates

Diluted EPS

Q2 2026-$1.71Miss by $0.91Q1 2026-$0.67Beat by $0.08Q4 2025-$0.45In line
Q3 2025-$0.61Miss by $0.04

FAQ

When did LB Pharmaceuticals Inc report Q3 2025 earnings?
LB Pharmaceuticals Inc (LBRX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were LB Pharmaceuticals Inc's Q3 2025 revenue and EPS?
LB Pharmaceuticals Inc reported eps of $-0.61 for Q3 2025.
Did LB Pharmaceuticals Inc beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.57 by $0.04.
Where can I find LB Pharmaceuticals Inc's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268154) and the 10-Q periodic report (0001193125-25-268174) directly on SEC EDGAR. The filing index links above go to sec.gov.